Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 15 Lung Neoplasms 5 Neoplasms 4 Neoplasm Metastasis 4 Hematologic Neoplasms 3 Neoplasms by Site 2 Neoplasms by Histologic Type 2 Lymphoproliferative Disorders 2 Lymphoma, Large-Cell, Anaplastic 2 Breast Neoplasms 2 Brain Neoplasms 2 Thyroid Neoplasms 1 Sexual Dysfunction, Physiological 1 Sarcoma 1 Rare Tumour 1 Rare Tumor 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuroblastoma 1 Lymphoma 1 Glioblastoma 1 Genomic Instability 1 Gastrointestinal Neoplasms 1 Eunuchism 1 Erectile Dysfunction 1 Disease Resistance 1 Colorectal Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1

Interventions

atezolizumab 1 alectinib 1 Vemurafenib 1 Neoadjuvant Therapy 1 Fruit 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Genomic Instability × alectinib × Clear all

NCT02314481 2026-05-04

DARWINII

University College, London

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Genomic Instability

Data powered by HemOnc (CC BY 4.0) Colophon ⚡